Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea
An et al.,
Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort..,
medRxiv, doi:10.1101/2020.07.04.20146548 (Preprint)
Retrospective of hospitalized patients with 31 HCQ patients and 195 standard treatment patients, not showing a significant difference in terms of viral clearance or recovery. There was no mortality in either group.
"It is notable that HQ plus antibiotics group had worse baseline clinical profiles (i.e. higher percentage of moderate severity patients, more patients with fever >=37.5C, higher average body temperature) and prognostic indicators such as age, LDH, lymphocyte count, and CRP".
We note that propensity score matching removed almost all of the male patients in the control group (40% -> 5%) but increased the percentage of male patients in the treatment group. This provides a large advantage to the control group because there is a very large difference in severity and mortality based on gender
[ncbi.nlm.nih.gov].
In terms of viral RNA clearance we note that other research has found that "active viral replication drops quickly after the first week, and viable virus was not found after the second week of illness despite the persistence of PCR detection of RNA”
[ams.edu.sg].
time to viral clearance, 3.0% lower, HR 0.97, p = 0.92, treatment 31, control 195.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
An et al., 7 Jul 2020, retrospective, South Korea, preprint, 12 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.07.04.20146548; this version posted July 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Treatment Response to Hydroxychloroquine and Antibiotics for mild to
moderate COVID-19: a retrospective cohort study from South Korea
Min Ho An, MD1,4*, Min Seo Kim, MD2,5*, Yu-Kyung Park, MD3, Bong-Ok Kim, MD, PhD3, Seok Ho
Kang, MD9, PhD, Won Jun Kim, MD2, Sung Kyu Park, MD3, Hea-Woon Park, MD, PhD3, Wonjong Yang,
MD3, Joonyoung Jang, MD3, Soon-Woo Jang, MD, KMD6,10, Tae-Ho Hwang, DSS, PhD7,8
*two authors contributed equally to this work
1
Ajou University, School of Medicine, Suwon, Republic of Korea
2
Korea University, College of Medicine, Seoul, Republic of Korea
3
Korea Workers’ Compensation & Welfare Services Daegu Hospital, 515 Hakjeong-ro, Buk-gu, Daegu,
Republic of Korea
4
Director of So Ahn Public Health Center, Wando, Republic of Korea
5
Director of Cheongsan Public Health Center, Wando, Republic of Korea
6
Director of Bukha Public Health Center, Jangseong, Republic of Korea
7
Department of Pharmacology, Pusan National University, School of Medicine, Yangsan, Republic of Korea
8
Gene and Cell Therapy Research Center for Vessel-associated Diseases, School of Medicine, Pusan
National University, Yangsan, Republic of Korea
9
Department of Urology, Korea University, School of Medicine, Seoul, Republic of Korea
10
Pusan University, School of Medicine, Yangsan, Republic of Korea
Corresponding author:
Soon-Woo Jang, MD, KMD6,10
Pusan University, School of Medicine, Yangsan, Republic of Korea
Director of Bukha Public Health Center, Jangseong, Republic of Korea
Phone : +82-10-88994593
E-mail : kmedicsoon@gmail.com
Tae-Ho Hwang, DSS, PhD7,8
Department of pharmacology, Pusan National University, School of Medicine, Yangsan, Republic of Korea
Director of Gene and Cell Therapy Research Center for Vessel-associated Diseases, School of Medicine,
Pusan National University, Yangsan, Republic of Korea
Phone: +82-10-71579950
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
E-mail : thhwang@pusan.ac.kr
medRxiv preprint doi: https://doi.org/10.1101/2020.07.04.20146548; this version posted July 7, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Keywords: COVID-19, Hydroxychloroquine, antibiotics, azithromycin, treatment response,
retrospective cohort study.
Short-Running Title: Response to pharmacological treatment of COVID-19
Total word count: abstract(235), total manuscript without abstract(2411)
Number of figures: 2
Number of tables: 3
Number of supplementary figures and tables: 1
Funding: The authors received no funding for this investigation
Declaration of Conflicting interest
The authors have no competing interests to disclose
Abstract
Objectives: To assess the efficacy of hydroxychloroquine on mild-moderate COVID-19 patients in South
Korea.
Methods: A retrospective cohort study of the 358 laboratory-confirmed SARS-CoV-2 (COVID-19) patients
was conducted. 226 patients met inclusion criteria for..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit